IL-2R Inhibitors
IL-2R inhibitors are a class of chemical compounds that specifically target and inhibit the activity of the interleukin-2 receptor (IL-2R), a crucial component of the immune signaling cascade. The IL-2 receptor is a multi-subunit protein complex that primarily consists of three subunits: alpha (IL-2Rα), beta (IL-2Rβ), and gamma (IL-2Rγ). These subunits come together to form a high-affinity receptor complex capable of binding to the cytokine interleukin-2 (IL-2). This binding initiates downstream signaling events that are essential for various immune processes, such as the activation and proliferation of T-cells. IL-2R inhibitors act by disrupting the interaction between IL-2 and its receptor, thereby modulating the signaling pathway and altering the cellular responses that follow.
The chemical structure of IL-2R inhibitors can vary, but they are often designed to block the receptor's interaction with IL-2 either by binding to one of the subunits of the receptor complex or by directly antagonizing IL-2 itself. Some inhibitors may specifically target the IL-2Rα subunit, which is unique to the high-affinity receptor, while others may interfere with the IL-2Rβ or IL-2Rγ subunits, which are shared with other cytokine receptors. By inhibiting IL-2R function, these compounds can regulate the downstream signaling pathways involved in immune cell growth and differentiation. IL-2R inhibitors are often used in research to study immune regulation, signaling cascades, and the molecular mechanisms that control immune cell activation and expansion, providing valuable insights into the complex interactions within the immune system.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Methotrexate | 59-05-2 | sc-3507 sc-3507A | 100 mg 500 mg | $92.00 $209.00 | 33 | |
Methotrexate may downregulate IL-2R expression by inhibiting dihydrofolate reductase, which leads to decreased nucleotide synthesis and reduced T cell proliferation, subsequently lowering IL-2R levels. | ||||||
hydroxychloroquine | 118-42-3 | sc-507426 | 5 g | $56.00 | 1 | |
Hydroxychloroquine could decrease IL-2R expression through lysosomal alkalinization in antigen-presenting cells, which attenuates antigen processing and T cell activation, resulting in fewer IL-2R molecules on the cell surface. | ||||||
Mycophenolic acid | 24280-93-1 | sc-200110 sc-200110A | 100 mg 500 mg | $68.00 $261.00 | 8 | |
Mycophenolic acid is thought to suppress IL-2R expression by selectively inhibiting guanosine nucleotide synthesis in lymphocytes, which disrupts their proliferation and activation. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $109.00 $350.00 | 8 | |
Thalidomide might reduce IL-2R expression by inhibiting the production of tumor necrosis factor-alpha (TNF-α), which is needed for the activation of T cells that express IL-2R. | ||||||
Lenalidomide | 191732-72-6 | sc-218656 sc-218656A sc-218656B | 10 mg 100 mg 1 g | $49.00 $367.00 $2030.00 | 18 | |
Lenalidomide may downregulate IL-2R expression by enhancing the degradation of transcription factors that control the IL-2R gene, leading to suppressed production of the receptor. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Imatinib could inhibit IL-2R expression by targeting ABL tyrosine kinases, which are involved in the T cell activation pathway that upregulates IL-2R expression. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $150.00 $920.00 | 5 | |
Sunitinib may decrease IL-2R expression by blocking platelet-derived growth factor receptors (PDGFRs), which play a role in signal transduction for T cell activation and IL-2R upregulation. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib could decrease IL-2R expression by inhibiting RAF kinases within the MAPK/ERK signaling pathway, thereby reducing T cell activation and subsequent IL-2R synthesis. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib might inhibit IL-2R expression by preventing the degradation of IκB, thereby keeping NF-κB inactive and unable to translocate to the nucleus to promote IL-2R gene transcription. | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $153.00 | 5 | |
Ibrutinib could reduce IL-2R expression by irreversibly binding to Bruton's tyrosine kinase (BTK), thus hindering B cell receptor signaling that would otherwise contribute to IL-2R upregulation. | ||||||